Conflict of interest and sources of funding statement This study was supported by grants from the Coordination of Improvement of Upper Level Personnel (CAPES) and from the Foundation for Support of Research in Minas Gerais (FAPEMIG/#13016). Authors report no conflicts of interest related to the present study.
Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus
Article first published online: 1 JUL 2010
© 2010 John Wiley & Sons A/S
Journal of Clinical Periodontology
Volume 37, Issue 10, pages 894–902, October 2010
How to Cite
Cota, L. O. M., Aquino, D. R., Franco, G. C. N., Cortelli, J. R., Cortelli, S. C. and Costa, F. O. (2010), Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus. Journal of Clinical Periodontology, 37: 894–902. doi: 10.1111/j.1600-051X.2010.01601.x
- Issue published online: 7 SEP 2010
- Article first published online: 1 JUL 2010
- Accepted for publication 4 June 2010
- gingival overgrowth;
- renal transplantation;
- risk factors;
Cota LOM, Aquino DR, Franco GCN, Cortelli JR, Cortelli SC, Costa FO. Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus. J Clin Periodontol 2010; 37: 894–902. doi: 10.1111/j.1600-051X.2010.01601.x.
Aim: To assess the prevalence and variables associated with gingival overgrowth (GO) in renal transplant recipients medicated with cyclosporine (CsA), tacrolimus (Tcr), or sirolimus (Sir).
Materials and Methods: One hundred and thirty-five eligible subjects were divided in CsA, Tcr, and Sir groups comprising 45 subjects each. GO was visually assessed and subjects were assigned as GO+ or GO− in a post hoc definition. Saliva samples were collected and the presence of periodontal pathogens was assessed through polymerase chain reaction. Variables of interest were compared between GO+ and GO− subjects through univariate and multivariate analysis.
Results: Prevalence of GO was of 60.0% for CsA, 28.9% for Tcr, and 15.6% for Sir groups. Within the CsA group, GO was associated with papillary bleeding index (p=0.001); within the Tcr group, GO was associated with CsA previous use (p=0.013), and calcium channel blockers (CCB) use (p=0.003); within the Sir group, GO was associated with papillary bleeding index (p=0.018), and CCB use (p=0.020). A higher frequency of Tannerella forsythia was observed among GO+ subjects medicated with Tcr.
Conclusion: Pharmacological and periodontal variables were associated with GO in different immunosuppressive regimens. Integration between the medical and the dental team may be an important approach in the post-transplant maintenance routine.